Telix Pharmaceuticals Ltd
TLXNasdaq
$10.46
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -33.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our company was incorporated under the laws of Australia in January 2017. Our headquarters and registered offices are located at 55 Flemington Road, North Melbourne, Victoria, 3051, Australia. Our agent for service of process in the United States is Telix Pharmaceuticals (US) Inc., located at 11700 Exit 5 Pkwy, Suite 200, Fishers, Indiana.
- CEO
- Christian Behrenbruch
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Website
- telixpharma.com
Management & directors
- Behrenbruch ChristianMD & Group CEO
- Smith Darren CharltonGroup Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 20, 2026
Jul 16, 2026
- 3d agoTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Studyfinance.yahoo.com
- 4d agoTelix opens radiopharmaceutical facility in Australia for cancer treatmentpharmaceutical-technology.com
- 4d agoTelix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturingfinance.yahoo.com
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-29 | Behrenbruch Christian· MD & Group CEO | Buy | 33,435 | $14.87 | $497,178.45 | filing |
| 2026-04-28 | Behrenbruch Christian· MD & Group CEO | Buy | 34,500 | $14.48 | $499,560.00 | filing |
| 2026-03-29 | Smith Darren Charlton· Group Chief Financial Officer | Option exercise | 1,111 | $0.00 | $0.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.